Transformation proceeds in a sequential manner with progressive transitions in a number of phenotypic characteristics. Similar results have been found in studies of animal and human cells treated repetitively with chemical carcinogens such as MNNG. One serious drawback to many of these studies is the lack of an identifiable and reproducible in vitro endpoint to distinguish full transformation. In our proposed studies we will use adult human endometrial cell that have been treated with MNNG in vitro and that demonstrate characteristics of human endometrial stromal cell tumors. We will also use cultured rat liver epithelial cells that have been similarly treated. We seek to test the hypothesis that a cell's ability to invade basement membrane, as monitored by a novel in vitro assay, is an in vitro phenotypic marker for full transformation. Further, we propose to examine if these fully transformed cells demonstrate concomitant alterations in expression of basement membrane proteins. We have recently shown that in a system of clonally derived cells, the invasive ability, as judged by this in vitro amnion model system, correlates and cosegregates with tumorigenicity. Work by us has also shown a significant inhibition of invasion by transformed human sarcoma cells after exposure to a novel anti-protease inhibitor. We therefore, further propose to test the hypothesis that the tumorigenic cells in this study can be chemically inhibited in vivo and that the amnion assay can serve as an in vitro measure of this ability. Our goals are: 1-To determine a quantifiable endpoint for malignant transformation in culture and 2-To use this same system as a monitor of the measure of chemical effects on fully transformed cells in vivo. If the hypothesis is supported by the weight of the experimental evidence this will give us the critical ability to accurately separate partial from full transformation. With this ability we can continue to elucidate the underlying mechanism(s) involved in tumor progression.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA045727-06
Application #
3458519
Study Section
Metabolic Pathology Study Section (MEP)
Project Start
1987-07-01
Project End
1993-05-31
Budget Start
1991-06-01
Budget End
1993-05-31
Support Year
6
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
Schools of Dentistry
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Siegal, G P; Wang, M H; Rinehart Jr, C A et al. (1993) Development of a novel human extracellular matrix for quantitation of the invasiveness of human cells. Cancer Lett 69:123-32
Helseth, A; Siegal, G P; Haug, E et al. (1992) Transgenic mice that develop pituitary tumors. A model for Cushing's disease. Am J Pathol 140:1071-80
Vollmer, G; Deerberg, F; Siegal, G P et al. (1991) Altered tenascin expression during spontaneous endometrial carcinogenesis in the BDII/Han rat. Virchows Arch B Cell Pathol Incl Mol Pathol 60:83-9
Lyn-Cook, B D; Siegal, G P; Kaufman, D G (1990) Malignant transformation of human endometrial stromal cells by transfection of c-myc: effects of pRSVneo cotransfection and treatment with MNNG. Pathobiology 58:146-52
Boyd, J A; Rinehart Jr, C A; Walton, L A et al. (1990) Ultrastructural characterization of two new human endometrial carcinoma cell lines and normal human endometrial epithelial cells cultured on extracellular matrix. In Vitro Cell Dev Biol 26:701-8
Kallianpur, A R; Carstens, P H; Liotta, L A et al. (1990) Immunoreactivity in malignant mesotheliomas with antibodies to basement membrane components and their receptors. Mod Pathol 3:11-8
Vollmer, G; Siegal, G P; Chiquet-Ehrismann, R et al. (1990) Tenascin expression in the human endometrium and in endometrial adenocarcinomas. Lab Invest 62:725-30